DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Advair Diskus (Fluticasone Propionate / Salmeterol Xinafoate Inhalation) - Published Studies

 
 



Advair Diskus Related Published Studies

Well-designed clinical trials related to Advair Diskus (Fluticasone / Salmeterol Xinafoate)

Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. [2011.03]

Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. [2010]

Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down". [2008.10]

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. [2007.07.14]

Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate. [2007.07]

The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. [2005.07]

Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. [2005.07]

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. [2005.06]

Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. [2005.06]

The 24 h duration of bronchodilator action of the salmeterol/fluticasone combination inhaler. [2005.05]

The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. [2005.04]

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. [2005.04]

[Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment] [2005.03]

Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. [2005.01]

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. [2004.11]

Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. [2004.10]

Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. [2004.06]

Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. [2004.01.24]

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. [2004]

Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. [2004]

[A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination] [2003.11]

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. [2003.10.18]

Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. [2003.09]

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. [2003.09]

Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. [2003.07]

Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. [2003.07]

Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate. [2003.07]

Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. [2003.05]

Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. [2003.05]

Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. [2003.05]

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. [2003.03]

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. [2003.02.08]

Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. [2003.01]

Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma. [2003]

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. [2002.10.15]

Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. [2002.06]

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. [2002.02]

Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. [2002]

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. [2002]

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone. [2001.09.01]

Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. [2001.05]

Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. [2001.02]

Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. [2001.01]

Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. [2001]

Additive effects of salmeterol and fluticasone or theophylline in COPD. [2000.12]

Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. [2000.08]

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. [2000.06]

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. [2000.02]

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. [1999.12]

Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. [1999.09]

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. [1999.04]

Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. [1999.03]

Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. [1999.03]

Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. [1999.01]

Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. [1998.03]

Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. [1997.04]

Well-designed clinical trials possibly related to Advair Diskus (Fluticasone / Salmeterol Xinafoate)

Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. [2006.06.19]

Initial corticosteroid therapy for asthma. [2006.01]

Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils. [2005.11]

Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? [2005.11]

[Is guideline-defined asthma control achievable?--secondary publication. The Gaining Optimal Asthma ControL (GOAL) Study] [2005.09.19]

An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions. [2005.09]

Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. [2005.09]

Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. [2005.06]

[Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease] [2005.03]

The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. [2005]

A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. [2004.11]

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. [2004.10.15]

The TORCH (towards a revolution in COPD health) survival study protocol. [2004.08]

Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. [2004]

Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. [2003.11]

Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. [2003.06]

Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. [2003.05.01]

Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. [2002.12]

Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. [2002.11]

Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma. [2001.07.01]

An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. [1999.11]

Treatment of nocturnal airway obstruction improves daytime cognitive performance in asthmatics. [1997.10]

Clinical evaluation of CFC-free metered dose inhalers. [1995.03]

Other research related to Advair Diskus (Fluticasone / Salmeterol Xinafoate)

Non-inferiority trial between two dry-powder inhalers containing fluticasone/salmeterol in asthmatic patients. [2013]

Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. [2011.10]

Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. [2011]

Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. [2010.02]

Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study. [2010]

Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. [2009.12]

Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products. [2009.02]

Darunavir: a review of its use in the management of HIV infection in adults. [2009]

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. [2007]

Management of chronic obstructive pulmonary disease associated with chronic bronchitis with inhaled fluticasone propionate/salmeterol (ADVAIR DISKUS) 250/50: results of a patient experience trial. [2006.03.29]

Anti-Inflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease. [2006.01.19]

Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. [2006.01]

[Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhalar compared to budesonide turbuhalar in the control of adult asthma] [2005.04]

Maintenance asthma treatment with fluticasone/salmeterol combination via Diskus: effect on outcomes in inner-city children enrolled in TennCare. [2005.03]

Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. [2005.02]

Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. [2005]

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. [2004.12]

Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. [2004.09]

Additive blockade of beta 2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate. [2004.04]

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. [2004.02]

Daptomycin. [2004]

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. [2004]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014